US equities |
MU $983.23 ▲+5.86% META $612.49 ▼-1.24% GOOGL $324.89 ▲+1.34% NVDA $215.38 ▼-1.17% MSFT $531.01 ▼-0.06% TSLA $404.22 ▼-0.80% SPCX $145.23 ▼-2.25% SNDK $1,404.77 ▲+7.66%
FinancialContent

Articles published by DBV Technologies S.A.

< Previous 1 2 3 4 Next >
News headline image
DBV Technologies to Participate in the Guggenheim Securities Emerging Outlook: Biotech Summit
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of January 31, 2026
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies Announces €166.7 Million in Gross Proceeds Following the Full Exercise of the ABSA Warrants and BS Warrants Issued on its March 2025 Financing
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
Information Regarding the Total number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of December 31, 2025
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies Announces Positive Topline Results from Phase 3 VITESSE Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of November 30, 2025
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies Announces Last Patient Visit Completed in VITESSE Phase 3 Clinical Trial of VIASKIN® Peanut Patch in Peanut Allergic Children Aged 4-7 Years
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies to Participate in the Guggenheim 2nd Annual Healthcare Innovation Conference
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of October 31, 2025
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies Announces Appointment of Philina Lee, Ph.D. to Board of Directors
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies to Participate in Upcoming ACAAI 2025 Annual Scientific Meeting
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies Reports Third Quarter 2025 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies Announces Sale of approximately $30 million of ADSs Through its At-The-Market (ATM) Program on Nasdaq
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies Announces Resignation of Board Member
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies Establishes an At-The-Market (ATM) Program on Nasdaq
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
Information regarding the total number of voting rights and total number of shares of the Company as of July 31, 2025
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies announces filing of 2025 Half-Year Report ― Conditions for accessing or consulting the Report
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies Reports Second Quarter and Half-Year 2025 Financial Results
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
Half-Year Report on the DBV Technologies Liquidity Contract with ODDO BHF
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies Announces Appointment of James Briggs as Chief Human Resources Officer
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies Announces First Subject Screened in COMFORT Toddlers Supplemental Safety Study in Peanut Allergic Toddlers 1 – 3 Years Old
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies to Participate in Upcoming EAACI Congress 2025
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies Announces the Voting Results of its 2025 Combined General Meeting
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
Information Regarding the Total Number of Voting Rights and Total Number of Shares of the Company as of May 30, 2025
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
News headline image
DBV Technologies announces the filing of an addendum to the 2024 Universal Registration Document
From DBV Technologies S.A.
Via GlobeNewswire
Tickers DBVT
< Previous 1 2 3 4 Next >